SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex Pharmaceuticals Incorporated and Its Board of Directors and a Lead Plaintiff Deadline of July 28, 2014 -- VRTX

NEW YORK, July 15, 2014 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") VRTX securities between May 7, 2012 and May 29, 2012.

For more information, click here: http://zlk.9nl.com/vertex-pharmaceuticals.

The complaint alleges that during the Class Period the Company made false and/or misleading statements regarding the positive nature of interim data from its Phase 2 study of the drugs VX-809 and Kalydeco.

On May 29, 2012, Vertex issued a series of press releases in which it acknowledged that the results from its clinical trials were not as positive as previously indicated. These results were further restated on June 28, 2012.

If you suffered a loss in Vertex you have until July 28, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/vertex-pharmaceuticals.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.